# EDGAR Filing Document

**Accession Number:** 0001668243
**File Stem:** 0001193125-25-269706
**Filing Date:** 2025-11
**Character Count:** 16673
**Document Hash:** 1f7095a18d0f238f841aa918fc58993d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-269706.hdr.sgml**: 20251106

**ACCESSION NUMBER**: 0001193125-25-269706

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 16

**FILED AS OF DATE**: 20251106

**DATE AS OF CHANGE**: 20251106

**EFFECTIVENESS DATE**: 20251106

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** UroGen Pharma Ltd.
- **CENTRAL INDEX KEY:** 0001668243
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-291325
- **FILM NUMBER:** 251458880

**BUSINESS ADDRESS:**
- **STREET 1:** 9 HA'TA'ASIYA ST
- **CITY:** RA'ANANA
- **STATE:** L3
- **ZIP:** 4365007
- **BUSINESS PHONE:** 972 9 770 7601

**MAIL ADDRESS:**
- **STREET 1:** 9 HA'TA'ASIYA ST
- **CITY:** RA'ANANA
- **STATE:** L3
- **ZIP:** 4365007

**As filed with the Securities and Exchange Commission on November 6, 2025** 

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM S-8** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## UroGen Pharma Ltd.
**(Exact name of registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **State of Israel** | **98-1460746** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer**<br> **Identification No.)** |
| **400 Alexander Park Drive, 4<sup>th</sup> Floor**<br> **Princeton, New Jersey** | **08540** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**2017 Equity Incentive Plan** 

**(Full titles of the plans)** 

**UroGen Pharma Ltd.** 

**Jason Smith** 

**General Counsel** 

**400 Alexander Park Drive, 4<sup>th</sup> Floor** 

**Princeton, New Jersey 08540** 

**Telephone: +1 (646) 768-9780** 

**(Name, address and telephone number, including area code, of agent for service)** 

***Copies to:***

**Charles J. Bair** 

**Asa M. Henin** 

**Cooley LLP** 

**10265 Science Center Drive** 

**San Diego, California 92121** 

**+1 (858) 550-6000** 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large Accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**INCORPORATION BY REFERENCE** 

This Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which Registration Statements of the Registrant on Form S-8 relating to the same employee benefit plan are effective. The Registrant previously registered its Ordinary Shares for issuance under the Registrant's 2017 Equity Incentive Plan under Registration Statements on Form S-8 filed with the Securities and Exchange Commission on [June 27, 2017](http://www.sec.gov/Archives/edgar/data/1668243/000119312517214607/d290281ds8.htm) (File No. 333-218992), [February 9, 2018](http://www.sec.gov/Archives/edgar/data/1668243/000119312518037821/d500049ds8.htm) (File No. 333-222955), [October 12, 2018](http://www.sec.gov/Archives/edgar/data/1668243/000119312518298488/d626890ds8.htm) (File No. 333-227812), [August 10, 2020](http://www.sec.gov/Archives/edgar/data/0001668243/000119312520215023/d944324ds8.htm) (File No. 333-243750), [August 5, 2021](http://www.sec.gov/Archives/edgar/data/0001668243/000119312521237825/d196947ds8.htm) (File No. 333-258496), [August 11, 2022](http://www.sec.gov/Archives/edgar/data/1668243/000119312522218027/d280171ds8.htm) (File No. 333-266761), [November 14, 2023](http://www.sec.gov/Archives/edgar/data/1668243/000119312523277126/d546131ds8.htm) (File No. 333-275547) and [August 13, 2024](http://www.sec.gov/Archives/edgar/data/1668243/000143774924026414/urgn20240719_s8.htm) (File No. 333-281520). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statements referenced above.

------

**ITEM 8. EXHIBITS.** 

---

| | |
|:---|:---|
| **Exhibit**<br> **Number** | **Description** |
| 4.1 | [Articles of Association of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant's Report on Form 6-K, furnished to the Securities and Exchange Commission on May 18, 2017).](http://www.sec.gov/Archives/edgar/data/1668243/000119312517175069/d401998dex31.htm) |
| 5.1 | [Opinion of Gornitzky & Co., Advocates, Israeli counsel to the Registrant, as to the validity of the Registrant's Ordinary Shares.](d938113dex51.htm) |
| 23.1 | [Consent of Independent Registered Public Accounting Firm.](d938113dex231.htm) |
| 23.2 | [Consent of Gornitzky & Co., Advocates Reference is made to Exhibit 5.1.](d938113dex51.htm) |
| 24.1 | [Powers of Attorney. Reference is made to the signature page hereto.](#sig) |
| 99.1 | [UroGen Pharma Ltd. 2017 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.2 to the Registrant's Current Report on Form 8-K, filed with the Commission on August 27, 2025).](http://www.sec.gov/Archives/edgar/data/1668243/000143774925027874/ex_857162.htm) |
| 107 | [Filing Fee Table](d938113dexfilingfees.htm) |

---

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Princeton, State of New Jersey, on November 6, 2025.

---

| | |
|:---|:---|
| **UROGEN PHARMA LTD.** | **UROGEN PHARMA LTD.** |
| By: | /s/ Elizabeth Barrett |
|  | Elizabeth Barrett |
|  | President and Chief Executive Officer |

---

**POWERS OF ATTORNEY** 

KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Elizabeth Barrett and Chris Degnan, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Elizabeth Barrett | President, Chief Executive Officer and Director | November 6, 2025 |
| Elizabeth Barrett | *(Principal Executive Officer)* |  |
| /s/ Chris Degnan | Chief Financial Officer | November 6, 2025 |
| Chris Degnan | *(Principal Financial and Accounting Officer)* |  |
| /s/ Arie Belldegrun | Chair | November 6, 2025 |
| Arie Belldegrun, M.D. |  |  |
| /s/ Cynthia Butitta | Director | November 6, 2025 |
| Cynthia Butitta |  |  |
| /s/ Leana S. Wen | Director | November 6, 2025 |
| Leana S. Wen, M.D., M.Sc. |  |  |
| /s/ Stuart Holden | Director | November 6, 2025 |
| Stuart Holden, M.D. |  |  |
| /s/ James Robinson Jr. | Director | November 6, 2025 |
| James Robinson Jr. |  |  |
| /s/ Daniel Wildman | Director | November 6, 2025 |
| Daniel Wildman |  |  |

---

## Exhibit 5.1

---

| | |
|:---|:---|
| ![LOGO](g938113g1105094835032.jpg) | **<u>Exhibit 5.1</u>** |

---

November 6, 2025

UroGen Pharma Ltd.

9 Ha'Ta'asiya Street

Raanana 4365007

<u>Israel</u> 

Re: **<u>Registration Statement on Form S-8</u>** 

Ladies/Gentlemen:

We have acted as Israeli counsel to UroGen Pharma Ltd., an Israeli company (the "**Company**"), in connection with its preparation of a Registration Statement on Form S-8 (the "**Registration Statement**") under the United States Securities Act of 1933, as amended (the "**Securities Act**"), relating to the registration of an additional 2,750,000 Ordinary Shares, NIS 0.01 par value per share, of the Company (the "**Plan Shares**") which may be issued under the Company's 2017 Equity Incentive Plan (the "**Plan**").

In connection with this opinion letter, we have examined originals or copies, certified or otherwise identified to our satisfaction, of: (i) the form of the Registration Statement; (ii) a copy of the articles of association of the Company, as currently in effect; (iii) the Plan; (iv) resolutions of the board of directors of the Company and the shareholders of the Company; and (v) such other corporate records, agreements, documents and other instruments, and such certificates or comparable documents of public officials and of officers and representatives of the Company, as we have deemed relevant and necessary as a basis for the opinions hereinafter set forth. We have also made inquiries of such officers and representatives of the Company as we have deemed relevant and necessary as a basis for the opinions hereinafter set forth.

In such examination, we have assumed the genuineness of all signatures, the legal capacity of all natural persons, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as copies, and the authenticity of the originals of such latter documents and the due execution and delivery of all documents by parties where due execution and delivery are a prerequisite to the effectiveness thereof. We have further assumed that the documents or copies thereof examined by us are true, complete and up-to-date and have not been amended, supplemented, rescinded, terminated or otherwise modified and that each individual grant under the Plan that has been made prior to the date hereof or will be made after the date hereof was and will be duly authorized by all necessary corporate action. As to all questions of fact relevant to the matters set forth herein, we did not independently establish or verify such facts and we have relied, without independent investigation, upon statements, certificates or comparable documents of officers or representatives of the Company and of public officials. We have considered such questions of Israeli law as we have deemed necessary for the purpose of rendering the opinions set forth herein.

![LOGO](g938113g1105094835251.jpg)

------

![LOGO](g938113g1105094835032.jpg)

Based on and subject to the assumptions, limitations and qualifications stated in this opinion letter, we are of the opinion that the Plan Shares, when issued and paid for pursuant to the terms of the Plan, the terms of any agreements relating to such issuance and the terms of the awards with respect thereto, will be duly authorized, validly issued, fully paid and non-assessable.

Our opinions herein are subject to and may be limited by the effect of applicable liquidation, bankruptcy, insolvency, composition, corporate rehabilitation, reorganization, moratorium, fraudulent conveyance or other similar laws affecting the rights of creditors.

We are members of the Bar of the State of Israel, and we express no opinion as to any matter relating to the laws of any jurisdiction other than the laws of Israel and have not, for the purpose of rendering the opinions set forth herein, made any investigation of the laws of any jurisdiction other than Israel.

This opinion letter is rendered as of the date hereof and the opinions expressed herein are based upon the laws of Israel that are in effect on the date hereof that have been published and are generally available on the date hereof, and we disclaim any obligation to advise you of any change of law that occurs, or of any facts, circumstances, events or developments of which we become aware, after the date of this opinion letter, even if they would alter, affect or modify the opinions expressed herein. This opinion letter is limited to the matters expressly stated herein and no opinion may be inferred or implied beyond the matters expressly stated herein to be our opinion.

We hereby consent to the filing of this opinion letter as Exhibit 5.1 to the Registration Statement. In giving such consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the United States Securities and Exchange Commission promulgated thereunder.

---

| |
|:---|
| Very truly yours, |
| *<u>/s/ Gornitzky & Co., Advocates</u>* |
| Gornitzky & Co., Advocates |

---

![LOGO](g938113g1105094835251.jpg)

## Exhibit 23.1

**Exhibit 23.1** 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of UroGen Pharma Ltd. of our report dated March 10, 2025 relating to the financial statements, which appears in UroGen Pharma Ltd.'s Annual Report on Form 10-K for the year ended December 31, 2024.

/s/ PricewaterhouseCoopers LLP

Florham Park, New Jersey

November 6, 2025

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**UroGen Pharma Ltd.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Security Type**  | **Security Class Title**  | **Fee Calculation Rule**  | **Amount Registered**  | **Proposed Maximum Offering Price Per Unit**  | **Maximum Aggregate Offering Price**  | **Fee Rate**  | **Amount of Registration Fee**  |
| 1 | Equity | Ordinary Shares, par value NIS 0.01 per share, to be issued pursuant to future awards under the UroGen Pharma Ltd. 2017 Equity Incentive Plan | Other | 2750000 | $19.68 | $54120000.00 | 0.0001381 | $7473.97 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $54120000.00  |  | $7473.97  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $7473.97  |

---

 **Offering Note** <br>

<sup>1</sup> Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional ordinary shares ("Ordinary Shares") of UroGen Pharma Ltd. (the "Registrant") that become issuable under the Registrant's 2017 Equity Incentive Plan (the "2017 Plan") by reason of any stock dividend, stock split, recapitalization or other similar transaction. The amount registered represents Ordinary Shares authorized for issuance under the 2017 Plan pursuant to an amendment to such plan that was approved by the Registrant's shareholders on August 26, 2025. The proposed maximum aggregate offering price per unit and the proposed maximum aggregate offering price for the 2,750,000 Ordinary Shares reserved for future grant under the 2017 Plan are made pursuant to Rule 457(c) and Rule 457(h)(1) of the Securities Act solely for the purpose of calculating the registration fee, and are based upon the average of the high and low prices of the Ordinary Shares on October 30, 2025, as reported on the Nasdaq Global Market.

---

| | |
|:---|:---|
| | |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---